title: Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
authors.affiliation: Department of Endocrinology and Diabetes, St Vincent's Hospital, Melbourne, Vic., Australia. jessieth@outlook.com.
authors.forename: Jessie
authors.initials: J
authors.lastname: Teng
authors.forename: Sally
authors.initials: S
authors.lastname: Abell
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Hicks
authors.forename: Michael S
authors.initials: MS
authors.lastname: Hofman
authors.forename: Nirupa
authors.initials: N
authors.lastname: Sachithanandan
authors.forename: Penny
authors.initials: P
authors.lastname: McKelvie
authors.forename: Richard J
authors.initials: RJ
authors.lastname: MacIsaac
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000069448:Denosumab; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D006996:Hypocalcemia / Q000139:chemically induced*; D008297:Male; D018358:Neuroendocrine Tumors / Q000150:complications / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000150:complications / Q000378:metabolism; D010257:Paraneoplastic Syndromes / Q000188:drug therapy* / Q000209:etiology; D044162:Parathyroid Hormone-Related Protein / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D044162:Parathyroid Hormone-Related Protein; D000069448:Denosumab